Agilent Technologies Inc Dossier
Qualitative Analysis
Business overview
Agilent Technologies Inc. (NYSE: A) is a premier global leader in life sciences, diagnostics, and applied chemical markets. Spun off from Hewlett-Packard in 1999, the company has established itself as a vital scientific partner, providing analytical laboratory instruments, software, services, and consumables to laboratories worldwide. Agilent operates through three primary business segments: Life Sciences and Diagnostics Markets Group (LDG), Agilent CrossLab Group (ACG), and Applied Markets Group (AMG). Its comprehensive portfolio—including liquid chromatography, gas chromatography, mass spectrometry, and tissue diagnostics—serves diverse end markets such as biopharma, clinical diagnostics, environmental testing, and food safety. The company's business model benefits from a massive global installed base of over 285,000 labs, driving high-margin, recurring revenue streams from consumables and service contracts.
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A company-wide operational framework designed to streamline business processes, optimize cost structures, and drive structural productivity and strategic pricing.
Expected impact: Contributes to gross margin improvements and supports the projected 85 basis points of non-GAAP operating margin expansion for fiscal 2026.
A strategic collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate customer-focused, AI-driven scientific innovation and integrate AI tools to speed up new product development.
Expected impact: Speeds up product development, modernizes scientific workflows, and digitizes laboratory operations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Expands Agilent's pathology portfolio through the addition of a highly complementary antibody, reagent, and instrument business. Strengthens Agilent's position in tissue diagnostics (IHC, ISH, and FISH) alongside its existing Dako pathology business.
Financial impact: Expected to be accretive to Agilent's top-line growth rate, margin profile, and non-instrument revenue mix in Year 1, and accretive to non-GAAP EPS approximately 12 months after closing. Adds approximately $90 million in annual revenue.
Strategic Partnerships
Aims to accelerate GLP-1 and complex biologics development in India by leveraging Agilent's advanced analytical technologies.
Terms: Not explicitly disclosed
Focuses on expanding and streamlining the Next-Generation Sequencing (NGS) workflow in the United States.
Terms: Not explicitly disclosed